Publications by authors named "Michael G Palazzolo"
Article Synopsis
- Heart failure is a common issue for patients with atrial fibrillation, making risk assessment crucial for clinicians.
- This study analyzed data from three large trials to evaluate how well NT-proBNP, hs-cTnT, and GDF-15 predict heart failure risk in these patients.
- Results showed that higher levels of these biomarkers correlate with a higher risk for cardiovascular death and heart failure-related hospitalization, enhancing the predictive accuracy of clinical assessments.
Article Synopsis
- * The ENGAGE AF-TIMI 48 trial involved a global double-blind study with 2966 older participants, comparing two dosing regimens of edoxaban and warfarin, focusing on those without dose-reduction criteria.
- * Key findings included a higher incidence of gastrointestinal hemorrhage associated with the 60 mg edoxaban dose, indicating the need for careful dose management in older patients on anticoagulants.
Article Synopsis
- The study investigates the effectiveness and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) in patients with varying body mass index (BMI) and body weight (BW), using data from the COMBINE AF trials.
- Results show that while the risk of stroke or embolic events decreases with higher BMI, the risk of major bleeding with NOACs remains stable across BMI levels, unlike with warfarin where it decreases.
- Overall, NOACs demonstrate a reduced risk for both stroke/SEE and major bleeding compared to warfarin, with consistent results across different BMI groups, although benefits diminish at higher BMI for major bleeding.
Background: Current clinical decision tools for assessing bleeding risk in individuals with atrial fibrillation (AF) have limited performance and were developed for individuals treated with warfarin. This study develops and validates a clinical risk score to personalize estimates of bleeding risk for individuals with atrial fibrillation taking direct-acting oral anticoagulants (DOACs).
Methods: Among individuals taking dabigatran 150 mg twice per day from 44 countries and 951 centers in this secondary analysis of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), a risk score was developed to determine the comparative risk for bleeding on the basis of covariates derived in a Cox proportional hazards model.
Background: The neutrophil-to-lymphocyte ratio (NLR) is the ratio between neutrophil and lymphocyte counts measured in peripheral blood. NLR is easily calculable based on a routine blood test available worldwide and may reflect systemic inflammation. However, the relationship between NLR and clinical outcomes in atrial fibrillation (AF) patients is not well-described.
View Article and Find Full Text PDFAims: The Atrial fibrillation Better Care (ABC) pathway is endorsed by guidelines to improve care of patients with atrial fibrillation (AF). However, whether the benefit of ABC pathway-concordant care is consistent across anticoagulants remains unclear. We assessed the association between ABC-concordant care and outcomes in this post hoc analysis from the ENGAGE AF-TIMI 48 trial, which was reported prior to the initial description of the ABC pathway.
View Article and Find Full Text PDF